Related Experiment Videos

Cost benefit analysis of Japanese encephalitis vaccination program in Thailand

T Siraprapasiri1, W Sawaddiwudhipong, S Rojanasuphot

  • 1Lampang Provincial Health Office, Ministry of Public Health, Lampang, Thailand.

Insights

Implementing the Japanese encephalitis (JE) vaccination program in Thai children at 18 months is more cost-effective than at 6 years. This JE immunization strategy offers significant health and economic benefits, preventing cases and reducing long-term care costs.

Area of Science:

  • Public Health
  • Epidemiology
  • Health Economics

Background:

  • Japanese encephalitis (JE) poses a significant public health threat, particularly in endemic regions like Thailand.
  • Vaccination is a key strategy for controlling JE transmission and preventing associated morbidity and mortality.

Purpose of the Study:

  • To estimate the benefits, risks, and costs of implementing a JE vaccination program in children aged 18 months and 6 years in Thailand.
  • To compare the cost-effectiveness of JE vaccination at two different age points.

Main Methods:

  • Decision analysis modeling was employed to evaluate the economic impact of JE vaccination programs.
  • Costs included vaccine procurement, administration, and societal costs associated with JE cases (treatment, disability, lost earnings).
  • Cost-effectiveness and cost-benefit analyses were conducted.

Main Results:

  • The JE vaccination program at 18 months costs $2.16 per person, while at 6 years it costs $3.68 per person.
  • The 18-month program is projected to prevent 124 JE cases, and the 6-year program 153 cases.
  • The 18-month program demonstrates superior cost-effectiveness ($15,715 per case prevented) compared to the 6-year program ($21,661 per case prevented).
  • The 18-month program yields higher savings ($72,922 per JE case prevented) than the 6-year program ($66,197 per JE case prevented).

Conclusions:

  • The Japanese encephalitis vaccination program is cost-beneficial in Thailand under baseline assumptions.
  • Implementing JE vaccination at 18 months is more cost-effective and yields greater economic benefits than at 6 years.
  • The program remains justifiable unless JE incidence falls below 3 per 100,000 population, necessitating potential vaccine cost reductions.

Related Concept Videos